Written by: Lisa Raff, PharmD, BCPS, BCOP Northwest Oncology & Hematology
Download Here

Treatment options for patients with carcinoid syndrome diarrhea that is refractory to somatostatin analog (SSA) therapy are limited. A first in class oral tryptophan hydroxylase inhibitor, telotristat ethyl, was approved in February for 2017 for use in combination with SSA therapy in adults with carcinoid syndrome diarrhea inadequately treated with SSA. Continue reading Telotristat ethyl: Carcinoid Syndrome Diarrhea

Read More

Written by: Ann Schwemm, PharmD, MPH, BCOP, University of Minnesota Health
Download Here

Cyclin-dependent kinase (CDK) 4/6 inhibitors have demonstrated significant advances in the treatment of hormone receptor (HR) positive and human epidermal growth factor receptor (HER2) negative advanced breast cancer. While current available data do not support the preferential use of one agent over the other, the dosing and safety monitoring differ and may help in treatment decision making with patients. Multi-disciplinary care teams have key roles in education and supportive care management to optimize the use of these agents and disease response1,2. Continue reading CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer

Read More

Written by: Neal Dave, PharmD and Julianne Orr, PharmD NCODA Spring Forum PQI Workshop
Download Here

Opioids are commonly utilized in the management of moderate to severe cancer pain. Constipation is a major side effect of opioid administration and should be assessed and managed by the healthcare team.
Continue reading Opioid Induced Constipation (OIC)

Read More

Written by: Bryan J. Brinda, PharmD
Download Here

This PQI will discuss proper patient selection and management of adverse events related to the administration of oral gilteritinib pharmacotherapy in patients with relapsed/refractory AML that have an FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test. Optimal patient identification, dosing, and follow-up are essential to help patients benefit fully while taking this medication. Continue reading Gilteritinib (XOSPATA) for Relapsed/Refractory Acute Myeloid Leukemia (AML)

Read More

Written by: Andrea Clarke, PharmD and Becky Fahrenbruch, PharmD, BCOP
Download Here

Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect that can occur with chemotherapeutics, including certain oral chemotherapy agents. Appropriate patient education and monitoring may assist with identifying early signs of peripheral neuropathy, but no agents have demonstrated efficacy in preventing CIPN. When patients experience chronic peripheral neuropathy not relieved by dose reductions or interruptions, further treatment may be warranted. Currently, the strongest evidence supports the use of duloxetine as treatment for CIPN. Other agents have demonstrated mixed results but may be useful for individual patients.
Continue reading Oral Chemotherapy-Induced Peripheral Neuropathy

Read More